by jmanor | Aug 12, 2022 | White Papers
A longstanding economic literature argues that the total welfare loss of a disease comes not only from the direct effects of the disease itself, but also the costs of preventing the disease. This paper assesses how new medical innovations for COVID-19—specifically...
by jmanor | Aug 11, 2022 | White Papers
From April 2020 through at least the end of 2021, Americans died from non-Covid causes at an average annual rate 97,000 in excess of previous trends. Hypertension and heart disease deaths combined were elevated 32,000. Diabetes or obesity, drug-induced causes, and...
by jmanor | Aug 3, 2022 | White Papers
This paper reviews the evidence covering the impact of biopharmaceuticals on the level and growth of total health care costs. The primary source of spending in health care is on labor, such as doctors, nurses or assistants, which makes up over 70% of overall spending,...
by jmanor | Jun 27, 2022 | White Papers
In February 2022, the Biden Administration aimed to reignite the Cancer Moonshot through its proposed federal budget and stated that one of its objectives is to reduce cancer mortality by 50% over the next 25 years. Currently, there is already a very large amount of...
by jmanor | May 16, 2022 | White Papers
There exists a large scientific literature on the value of improved health and how to incorporate that value into policy and decision making where activities impact health outcomes. The purpose of this policy brief is to review literature on the value of health in...
